董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gilles Gagnon | 男 | Director | -- | 未披露 | 未持股 | 2019-12-31 |
| Brent Norton | 男 | Director | -- | 未披露 | 未持股 | 2019-12-31 |
| Klaus Paulini | 男 | President, Chief Executive Officer and Director, Managing Director AEZS Germany | -- | 未披露 | 未持股 | 2019-12-31 |
| Robin Smith Hoke | 女 | Director | 62 | 未披露 | 未持股 | 2019-12-31 |
| Gerard Limoges | 男 | Director | -- | 6.11万美元 | 0.12 | 2019-12-31 |
| Carolyn Egbert | 女 | Director, Chair of the Board | -- | 7.03万美元 | 0.19 | 2019-12-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Eckhard Guenther | 男 | Vice President Business Development & Alliance Management,Managing Director AEZS Germany | -- | 未披露 | 未持股 | 2019-12-31 |
| Nicola Ammer | 女 | Chief Medical Officer, Vice President Clinical Development | -- | 未披露 | 未持股 | 2019-12-31 |
| Leslie Auld | 女 | Senior Vice President, Chief Financial Officer | -- | 未披露 | 未持股 | 2019-12-31 |
| Matthias Gerlach | 男 | Vice President Manufacturing and Supply Chain | -- | 未披露 | 未持股 | 2019-12-31 |
| Guenther Grau | 男 | Vice President Finance | -- | 未披露 | 未持股 | 2019-12-31 |
| Klaus Paulini | 男 | President, Chief Executive Officer and Director, Managing Director AEZS Germany | -- | 未披露 | 未持股 | 2019-12-31 |
董事简历
中英对照 | 中文 | 英文- Gilles Gagnon
-
Gilles Gagnon目前是CEAPRO公司的总裁兼首席执行官。在此之前，他是Aeterna Zentaris Inc.的总裁兼首席执行官。在过去的35年中，Gagnon先生在健康领域，特别是在医院环境和制药行业的多个管理层任职。Gagnon先生曾参与多个国际委员会和战略咨询委员会。他曾任职加拿大研究制药公司RX&D-Now Innovative Medicine Canada的董事会9年，在那里他曾代表生物制药部门的成员，并开创RX&D&；8217；S加拿大生物制药计划。他目前是Innovative Medicine Canada的首席执行官理事会成员。他是一名获得认证的Corporate Director，在多伦多大学罗特曼管理学院完成了董事教育课程，并曾在生物制药领域的多家私营和上市公司的董事会任职。
Gilles Gagnon is currently the President and Chief Executive Officer of Ceapro Inc. Prior to that, he was President and CEO of Aeterna Zentaris Inc. During the past 35 years, Mr. Gagnon has worked at several management levels within the field of health, especially in the hospital environment and pharmaceutical industry. Mr. Gagnon has participated in several international committees and strategic advisory boards. He served nine years on the board of directors of Canada’s Research Based Pharmaceutical Companies Rx&D-now Innovative Medicine Canada where he represented members from the biopharmaceutical sector and pioneered the Rx&D’s Canadian Biopartnering initiative. He is currently a member of the CEO Council of Innovative Medicine Canada. He is a certified corporate Director having completed the Directors Education Program at the Rotman School of Management at the University of Toronto and he has served on several boards of both private and publicly listed companies in the biopharmaceutical sector. - Gilles Gagnon目前是CEAPRO公司的总裁兼首席执行官。在此之前，他是Aeterna Zentaris Inc.的总裁兼首席执行官。在过去的35年中，Gagnon先生在健康领域，特别是在医院环境和制药行业的多个管理层任职。Gagnon先生曾参与多个国际委员会和战略咨询委员会。他曾任职加拿大研究制药公司RX&D-Now Innovative Medicine Canada的董事会9年，在那里他曾代表生物制药部门的成员，并开创RX&D&；8217；S加拿大生物制药计划。他目前是Innovative Medicine Canada的首席执行官理事会成员。他是一名获得认证的Corporate Director，在多伦多大学罗特曼管理学院完成了董事教育课程，并曾在生物制药领域的多家私营和上市公司的董事会任职。
- Gilles Gagnon is currently the President and Chief Executive Officer of Ceapro Inc. Prior to that, he was President and CEO of Aeterna Zentaris Inc. During the past 35 years, Mr. Gagnon has worked at several management levels within the field of health, especially in the hospital environment and pharmaceutical industry. Mr. Gagnon has participated in several international committees and strategic advisory boards. He served nine years on the board of directors of Canada’s Research Based Pharmaceutical Companies Rx&D-now Innovative Medicine Canada where he represented members from the biopharmaceutical sector and pioneered the Rx&D’s Canadian Biopartnering initiative. He is currently a member of the CEO Council of Innovative Medicine Canada. He is a certified corporate Director having completed the Directors Education Program at the Rotman School of Management at the University of Toronto and he has served on several boards of both private and publicly listed companies in the biopharmaceutical sector.
- Brent Norton
-
Brent Norton自2018年以来一直担任董事会董事。Norton博士是生命科学行业的业务领导者，在几家成功的企业中拥有运营和董事经验，这些企业为投资者实现了可观的产品销售和回报。他利用他的跨职能知识在学术界和商界发展战略、筹集资本和建立重要的关系。Norton博士创立了PreMD，完成了IPO并在多伦多证券交易所和美国证券交易所上市。在运营方面，他拥有研究与开发和商业运营业务，领导了与阿斯利康、礼来、欧莱雅、派克戴维斯/辉瑞等公司的交易，并通过FDA将产品带到强生公司的全球许可之外。他是Novadaq Technologies TSX:NDQ，NASDAQ:NVDQ的创始董事，最近被出售给史赛克公司。Norton博士一直是加拿大和美国几个董事会的活跃成员，他是Lumira Capital的风险合伙人，Ortho RTI的执行主席兼首席执行官，Camh的研究委员会成员，Ivey International Centre for Health Innovation的顾问BOD成员，Alpine Ontario的董事和Osler Bluff滑雪俱乐部的前任总裁和董事。
Brent Norton has served as a director on our Board since 2018. Dr. Norton is a business leader in the life science industry with operational and director experience across several successful enterprises which have achieved significant product sales and returns for investors. He uses his cross functional knowledge to develop strategy, raise capital and build important relationships in the academic and business community. Dr. Norton founded PreMD, completing IPO’s and listings on both the Toronto Stock Exchange and the American Stock Exchange. Operationally, he has research and development and commercial operations, led transactions with AstraZeneca, Eli Lilly, L’Oreal, Parke Davis/Pfizer, etc., and taken products through the FDA to global out-licensing with Johnson & Johnson. He is a founding Director of Novadaq Technologies TSX:NDQ, NASDAQ:NVDQ and was recently sold to Stryker Corporation. Dr. Norton has been an active member of several boards in Canada and the U.S. He is a Venture Partner at Lumira Capital, Executive Chairman & CEO of Ortho RTI, a member of the Research Committee for CAMH, an Advisory BOD member for the Ivey International Centre for Health Innovation, a Director of Alpine Ontario and Past-President and Director of the Osler Bluff Ski Club. - Brent Norton自2018年以来一直担任董事会董事。Norton博士是生命科学行业的业务领导者，在几家成功的企业中拥有运营和董事经验，这些企业为投资者实现了可观的产品销售和回报。他利用他的跨职能知识在学术界和商界发展战略、筹集资本和建立重要的关系。Norton博士创立了PreMD，完成了IPO并在多伦多证券交易所和美国证券交易所上市。在运营方面，他拥有研究与开发和商业运营业务，领导了与阿斯利康、礼来、欧莱雅、派克戴维斯/辉瑞等公司的交易，并通过FDA将产品带到强生公司的全球许可之外。他是Novadaq Technologies TSX:NDQ，NASDAQ:NVDQ的创始董事，最近被出售给史赛克公司。Norton博士一直是加拿大和美国几个董事会的活跃成员，他是Lumira Capital的风险合伙人，Ortho RTI的执行主席兼首席执行官，Camh的研究委员会成员，Ivey International Centre for Health Innovation的顾问BOD成员，Alpine Ontario的董事和Osler Bluff滑雪俱乐部的前任总裁和董事。
- Brent Norton has served as a director on our Board since 2018. Dr. Norton is a business leader in the life science industry with operational and director experience across several successful enterprises which have achieved significant product sales and returns for investors. He uses his cross functional knowledge to develop strategy, raise capital and build important relationships in the academic and business community. Dr. Norton founded PreMD, completing IPO’s and listings on both the Toronto Stock Exchange and the American Stock Exchange. Operationally, he has research and development and commercial operations, led transactions with AstraZeneca, Eli Lilly, L’Oreal, Parke Davis/Pfizer, etc., and taken products through the FDA to global out-licensing with Johnson & Johnson. He is a founding Director of Novadaq Technologies TSX:NDQ, NASDAQ:NVDQ and was recently sold to Stryker Corporation. Dr. Norton has been an active member of several boards in Canada and the U.S. He is a Venture Partner at Lumira Capital, Executive Chairman & CEO of Ortho RTI, a member of the Research Committee for CAMH, an Advisory BOD member for the Ivey International Centre for Health Innovation, a Director of Alpine Ontario and Past-President and Director of the Osler Bluff Ski Club.
- Klaus Paulini
-
Klaus Paulini于2019年10月被任命为公司总裁兼首席执行官，并担任董事会董事。Paulini博士位于德国法兰克福，隶属于我们的子公司AEZS Germany，他于2019年7月被任命为董事总经理，并于2018年2月被任命为Vice President质量和监管机构。Paulini博士于1997年在ASTA Medica AG开始了他的制药行业职业生涯。他曾在Zentaris公司从ASTA Medica公司成立和剥离时发挥积极作用，并担任公司的多种职务，并不断被提拔，包括Cetrotide公司的项目责任。作为质量保证主管，Paulini博士成功地管理了我们的许多临床开发项目——包括Macrilen™；/Macimorelin——处于研发阶段，担任集团领导药物化学。凭借丰富的经验和知识，他为我们的制药和临床开发计划提供了成功的监督和宝贵的投入，确保成功和合规的结果，最终导致美国FDA和EMA的监管批准。Paulini博士获得博士学位ING博士。1993年在达姆施塔特工业大学（德国）获得化学博士学位，在加入ASTA Medica AG之前，在斯特拉斯克莱德大学（苏格兰格拉斯哥）和J.W.歌德大学（德国法兰克福）获得博士后奖学金期间专门从事药物化学/药物发现。
Klaus Paulini was appointed President and Chief Executive Officer of the Company in October 2019 and also serves as a director on our Board. Dr. Paulini is based in Frankfurt, Germany at our subsidiary AEZS Germany, where he was appointed Managing Director in July 2019 and as Vice President Quality and Regulatory in February 2018. Dr. Paulini began his career in the pharmaceutical industry at ASTA Medica AG in 1997. He had an active role when Zentaris was formed and spun out of ASTA Medica, and served in various roles with increasing responsibility at the company ever since, including project responsibility for Cetrotide®. As Head of Quality Assurance, Dr. Paulini successfully managed many of our clinical development projects - including Macrilen™/Macimorelin - in R&D phase as group leader medicinal chemistry. With his extensive experience and knowledge, he provided successful oversight and valuable input for our pharmaceutical and clinical development programs, ensuring successful and compliant outcomes, ultimately leading to regulatory approvals by the US FDA and the EMA. Dr. Paulini obtained his PhD Dr. Ing. in chemistry at the Technical University Darmstadt (Germany) in 1993 and specialized in medicinal chemistry/drug discovery during subsequent postdoctoral fellowships at Strathclyde University (Glasgow, Scotland) and J.W. Goethe University (Frankfurt, Germany) before joining ASTA Medica AG. - Klaus Paulini于2019年10月被任命为公司总裁兼首席执行官，并担任董事会董事。Paulini博士位于德国法兰克福，隶属于我们的子公司AEZS Germany，他于2019年7月被任命为董事总经理，并于2018年2月被任命为Vice President质量和监管机构。Paulini博士于1997年在ASTA Medica AG开始了他的制药行业职业生涯。他曾在Zentaris公司从ASTA Medica公司成立和剥离时发挥积极作用，并担任公司的多种职务，并不断被提拔，包括Cetrotide公司的项目责任。作为质量保证主管，Paulini博士成功地管理了我们的许多临床开发项目——包括Macrilen™；/Macimorelin——处于研发阶段，担任集团领导药物化学。凭借丰富的经验和知识，他为我们的制药和临床开发计划提供了成功的监督和宝贵的投入，确保成功和合规的结果，最终导致美国FDA和EMA的监管批准。Paulini博士获得博士学位ING博士。1993年在达姆施塔特工业大学（德国）获得化学博士学位，在加入ASTA Medica AG之前，在斯特拉斯克莱德大学（苏格兰格拉斯哥）和J.W.歌德大学（德国法兰克福）获得博士后奖学金期间专门从事药物化学/药物发现。
- Klaus Paulini was appointed President and Chief Executive Officer of the Company in October 2019 and also serves as a director on our Board. Dr. Paulini is based in Frankfurt, Germany at our subsidiary AEZS Germany, where he was appointed Managing Director in July 2019 and as Vice President Quality and Regulatory in February 2018. Dr. Paulini began his career in the pharmaceutical industry at ASTA Medica AG in 1997. He had an active role when Zentaris was formed and spun out of ASTA Medica, and served in various roles with increasing responsibility at the company ever since, including project responsibility for Cetrotide®. As Head of Quality Assurance, Dr. Paulini successfully managed many of our clinical development projects - including Macrilen™/Macimorelin - in R&D phase as group leader medicinal chemistry. With his extensive experience and knowledge, he provided successful oversight and valuable input for our pharmaceutical and clinical development programs, ensuring successful and compliant outcomes, ultimately leading to regulatory approvals by the US FDA and the EMA. Dr. Paulini obtained his PhD Dr. Ing. in chemistry at the Technical University Darmstadt (Germany) in 1993 and specialized in medicinal chemistry/drug discovery during subsequent postdoctoral fellowships at Strathclyde University (Glasgow, Scotland) and J.W. Goethe University (Frankfurt, Germany) before joining ASTA Medica AG.
- Robin Smith Hoke
-
Robin Smith Hoke，2015年12月以来，她一直担任Outlook Therapeutics, Inc.董事会的成员。2012年7月以来，她一直担任代理顾问，为跨国、中间层和新兴公司和私人股本公司提供医药卫生咨询服务。此前，她曾担任Ricerca Biosciences公司（一个临床前合同研究组织）的多种职务，包括董事会成员（2013年2月至2015年12月）、董事会成员（从2013年2月到2015年12月）、董事会成员兼临时首席执行官（从2013年8月到2014年2月）。此前，她曾担任GeneralMedix Pharmaceuticals公司（一个私营专业注射公司）的总裁（从2007年7月到2012年6月）。她也曾担任Cardinal Health公司（医疗保健公司）的高级副总裁，负责仿制药品的全球业务发展和战略举措（2005年至2007年），也曾担任总法律顾问（2001年至2005年）。此前，她曾担任Abbott Laboratories公司（医疗保健公司）的内部法律顾问，以及Kegler, Brown, Hill & Ritter Co., LP（律师事务所）的商业合伙人。她持有Michigan State University的学士学位，以及Thomas M. Cooley Law School的法学博士学位。
Robin Smith Hoke has served as a director on our Board since 2018. Ms. Hoke is a business and legal executive with over 25 years of healthcare and pharmaceutical experience in various legal and business roles where she focused on operations, strategy, business development, acquisitions, strategic relationships, and commercialization. Ms. Hoke currently serves as President & CEO of Leiters, a 503B FDA registered outsourcing service provider with manufacturing facilities in Denver, Colorado and San Jose, California. She also serves as a member of the board of directors of Camargo Pharmaceutical Services, LLC, a privately held 505b(2) global drug development and regulatory services company in Cincinnati, Ohio. She previously served as a member of the board of Oncobiologics, Inc., a publicly held clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. She previously served as chair of the board of directors and interim chief executive officer at Ricerca Biosciences, LLC, a pre-clinical CRO. Prior to Ricerca, Ms. Hoke served as the president of GeneraMedix, Inc., a specialty generic injectable company and held senior legal and business roles at Cardinal Health, Inc. She also spent time with Abbott Laboratories, Inc., and served as a partner in the business law firm of Kegler, Brown, Hill & Ritter, Co., L.P.A. - Robin Smith Hoke，2015年12月以来，她一直担任Outlook Therapeutics, Inc.董事会的成员。2012年7月以来，她一直担任代理顾问，为跨国、中间层和新兴公司和私人股本公司提供医药卫生咨询服务。此前，她曾担任Ricerca Biosciences公司（一个临床前合同研究组织）的多种职务，包括董事会成员（2013年2月至2015年12月）、董事会成员（从2013年2月到2015年12月）、董事会成员兼临时首席执行官（从2013年8月到2014年2月）。此前，她曾担任GeneralMedix Pharmaceuticals公司（一个私营专业注射公司）的总裁（从2007年7月到2012年6月）。她也曾担任Cardinal Health公司（医疗保健公司）的高级副总裁，负责仿制药品的全球业务发展和战略举措（2005年至2007年），也曾担任总法律顾问（2001年至2005年）。此前，她曾担任Abbott Laboratories公司（医疗保健公司）的内部法律顾问，以及Kegler, Brown, Hill & Ritter Co., LP（律师事务所）的商业合伙人。她持有Michigan State University的学士学位，以及Thomas M. Cooley Law School的法学博士学位。
- Robin Smith Hoke has served as a director on our Board since 2018. Ms. Hoke is a business and legal executive with over 25 years of healthcare and pharmaceutical experience in various legal and business roles where she focused on operations, strategy, business development, acquisitions, strategic relationships, and commercialization. Ms. Hoke currently serves as President & CEO of Leiters, a 503B FDA registered outsourcing service provider with manufacturing facilities in Denver, Colorado and San Jose, California. She also serves as a member of the board of directors of Camargo Pharmaceutical Services, LLC, a privately held 505b(2) global drug development and regulatory services company in Cincinnati, Ohio. She previously served as a member of the board of Oncobiologics, Inc., a publicly held clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. She previously served as chair of the board of directors and interim chief executive officer at Ricerca Biosciences, LLC, a pre-clinical CRO. Prior to Ricerca, Ms. Hoke served as the president of GeneraMedix, Inc., a specialty generic injectable company and held senior legal and business roles at Cardinal Health, Inc. She also spent time with Abbott Laboratories, Inc., and served as a partner in the business law firm of Kegler, Brown, Hill & Ritter, Co., L.P.A.
- Gerard Limoges
-
Gerard Limoges， 自2004年以来一直担任本公司董事。直至1999年9月退休前，他担任安永会计师事务所加拿大分部副董事长。在安永37年的职业生涯结束后，他致力于担任多个公司的董事。他的职业生涯始于1992年，安永会计师事务所，蒙特利尔办事处。1996年，从蒙特利尔大学管理学院毕业，同年他参加了亚信考试（获得荣誉：加拿大最高分总督金奖、魁北克金奖the Ordre des Comptables Agrs du ）。1967年，他成为特许会计师，1971年成为安永合伙人。他从1962年开始从事审计师执业，1971年起担任合伙人，1979年被任命为蒙特利尔办事处管理合伙人；1984年，他成为魁北克办事处董事长，同时他还加入了全国执行委员会。1992年，他被任命为安永加拿大副董事长，并于次年担任安永加拿大公司的代理董事长。1999年9月，个人执业结束后，他被任命为蒙特利尔学校理事会理事、魁北克卫生保健与社会服务委员会成员（2000-2001年）、蒙特利尔大学及附属学校校长的特别顾问（2000-2003年）。应蒙特利尔大学的董事会的要求，他参加了2011年医学院院长的选举。他是以下上市公司的董事，或理事，及审核委员会主席：Aeterna Zentaris Inc. （多伦多证交所及纳斯达克）， Hartco Inc. （多伦多证交所）， PROREIT （多伦多证交所） 和 Hart Stores Inc. （多伦多创业板）。他还是多家私人公司和慈善机构的董事会成员。他于1984年成为注册法务会计师、资深皇家特许会计师，并于2002年获得加拿大勋章。
Gerard Limoges has served as a director on our Board since 2004. Mr. Limoges served as the Deputy Chairman of Ernst & Young LLP Canada until his retirement in September 1999. After a career of 37 years with Ernst & Young, Mr. Limoges has been devoting his time as a director of a number of companies. Mr. Limoges began his career with Ernst & Young in Montreal in 1962. After graduating from the Management Faculty of the Université de Montréal HEC Montréal in 1966 he wrote the CICA exams the same year (Honors: Governor General’s Gold Medal for the highest marks in Canada and Gold Medal of the Ordre des Comptables Agréés du Québec). He became a chartered accountant in 1967 and partner of Ernst & Young in 1971. After practicing as auditor since 1962 and partner since 1971 he was appointed Managing Partner of the Montreal Office in 1979 and Chairman for Quebec in 1984 when he also joined the National Executive Committee. In 1992 he was appointed Vice Chairman of Ernst & Young Canada and the following year, Deputy Chairman of the Canadian firm. After retirement from practice at the end of September 1999 he was appointed Trustee of the School Board of Greater Montreal -1999 member of the Quebec Commission on Health Care and Social Services (2000-2001) and special advisor to the Rector of the Université de Montréal and affiliate schools (2000-2003). Mr. Limoges, at the request of the board of directors of the Université de Montréal, participated in the selection of the Dean of the Faculty of Medicine in 2011. Mr. Limoges is also a trustee and chairman of the Audit Committee of PROREIT (TSX). He is also a board member of various private companies and charities. Mr. Limoges became an FCPA, FCA (Fellow) in 1984 and received the Order of Canada in 2002. - Gerard Limoges， 自2004年以来一直担任本公司董事。直至1999年9月退休前，他担任安永会计师事务所加拿大分部副董事长。在安永37年的职业生涯结束后，他致力于担任多个公司的董事。他的职业生涯始于1992年，安永会计师事务所，蒙特利尔办事处。1996年，从蒙特利尔大学管理学院毕业，同年他参加了亚信考试（获得荣誉：加拿大最高分总督金奖、魁北克金奖the Ordre des Comptables Agrs du ）。1967年，他成为特许会计师，1971年成为安永合伙人。他从1962年开始从事审计师执业，1971年起担任合伙人，1979年被任命为蒙特利尔办事处管理合伙人；1984年，他成为魁北克办事处董事长，同时他还加入了全国执行委员会。1992年，他被任命为安永加拿大副董事长，并于次年担任安永加拿大公司的代理董事长。1999年9月，个人执业结束后，他被任命为蒙特利尔学校理事会理事、魁北克卫生保健与社会服务委员会成员（2000-2001年）、蒙特利尔大学及附属学校校长的特别顾问（2000-2003年）。应蒙特利尔大学的董事会的要求，他参加了2011年医学院院长的选举。他是以下上市公司的董事，或理事，及审核委员会主席：Aeterna Zentaris Inc. （多伦多证交所及纳斯达克）， Hartco Inc. （多伦多证交所）， PROREIT （多伦多证交所） 和 Hart Stores Inc. （多伦多创业板）。他还是多家私人公司和慈善机构的董事会成员。他于1984年成为注册法务会计师、资深皇家特许会计师，并于2002年获得加拿大勋章。
- Gerard Limoges has served as a director on our Board since 2004. Mr. Limoges served as the Deputy Chairman of Ernst & Young LLP Canada until his retirement in September 1999. After a career of 37 years with Ernst & Young, Mr. Limoges has been devoting his time as a director of a number of companies. Mr. Limoges began his career with Ernst & Young in Montreal in 1962. After graduating from the Management Faculty of the Université de Montréal HEC Montréal in 1966 he wrote the CICA exams the same year (Honors: Governor General’s Gold Medal for the highest marks in Canada and Gold Medal of the Ordre des Comptables Agréés du Québec). He became a chartered accountant in 1967 and partner of Ernst & Young in 1971. After practicing as auditor since 1962 and partner since 1971 he was appointed Managing Partner of the Montreal Office in 1979 and Chairman for Quebec in 1984 when he also joined the National Executive Committee. In 1992 he was appointed Vice Chairman of Ernst & Young Canada and the following year, Deputy Chairman of the Canadian firm. After retirement from practice at the end of September 1999 he was appointed Trustee of the School Board of Greater Montreal -1999 member of the Quebec Commission on Health Care and Social Services (2000-2001) and special advisor to the Rector of the Université de Montréal and affiliate schools (2000-2003). Mr. Limoges, at the request of the board of directors of the Université de Montréal, participated in the selection of the Dean of the Faculty of Medicine in 2011. Mr. Limoges is also a trustee and chairman of the Audit Committee of PROREIT (TSX). He is also a board member of various private companies and charities. Mr. Limoges became an FCPA, FCA (Fellow) in 1984 and received the Order of Canada in 2002.
- Carolyn Egbert
-
Carolyn Egbert，自2012年8月起担任本公司董事。在密歇根州和华盛顿特区从事辩护诉讼律师之后，她加入了位于德克萨斯州休斯敦的美国苏威公司“苏威”（化学制药公司）。在苏威20年的职业生涯中，她担任过多个职务：人力资源副总裁、苏威管理服务总裁、人力资源全球主管、全球道德与合规部高级执行副总裁。在苏威的任职期间，她曾担任过7家子公司的董事。2010年退休后，她成立了一个咨询公司，提供公司治理、道德与合规、组织发展和战略性人力资源方面的专业知识咨询服务。她获得了华盛顿特区的乔治·华盛顿大学生物学学士学位，和华盛顿州西雅图大学的法律博士学位。她也曾是华盛顿特区的乔治敦大学医学院，和伊利诺伊州芝加哥西北大学医学院的药理学博士生。她依然活跃在密歇根州和哥伦比亚特区的律师业。
Carolyn Egbert has served as a director on our Board since August 2012 and as Chair of our Board since May 2016. After enjoying the private practice of law as a defense litigator in Michigan and Washington, D.C., she joined Solvay America, Inc. “Solvay” (a chemical and pharmaceutical company) in Houston, Texas. Over the course of a twenty-year career with Solvay, she held the positions of Vice President, Human Resources, President of Solvay Management Services, Global Head of Human Resources and Senior Executive Vice President of Global Ethics and Compliance. During her tenure with Solvay, she served as a director on the board of directors of seven subsidiary companies and as Chair of one subsidiary board. After retiring in 2010 she established a consulting business providing expertise in corporate governance, ethics and compliance, organizational development, executive compensation and strategic human resources. She holds a Bachelor of Sciences degree in Biological Sciences from George Washington University, Washington D.C. and a Juris Doctor degree from Seattle University, Seattle, Washington. She also was a Ph.D. candidate in Pharmacology at both Georgetown University Medical School at Washington, D.C. and Northwestern University Medical School at Chicago, Illinois. She remains an active member of both the Michigan State Bar and the District of Columbia Bar, Washington, D.C. - Carolyn Egbert，自2012年8月起担任本公司董事。在密歇根州和华盛顿特区从事辩护诉讼律师之后，她加入了位于德克萨斯州休斯敦的美国苏威公司“苏威”（化学制药公司）。在苏威20年的职业生涯中，她担任过多个职务：人力资源副总裁、苏威管理服务总裁、人力资源全球主管、全球道德与合规部高级执行副总裁。在苏威的任职期间，她曾担任过7家子公司的董事。2010年退休后，她成立了一个咨询公司，提供公司治理、道德与合规、组织发展和战略性人力资源方面的专业知识咨询服务。她获得了华盛顿特区的乔治·华盛顿大学生物学学士学位，和华盛顿州西雅图大学的法律博士学位。她也曾是华盛顿特区的乔治敦大学医学院，和伊利诺伊州芝加哥西北大学医学院的药理学博士生。她依然活跃在密歇根州和哥伦比亚特区的律师业。
- Carolyn Egbert has served as a director on our Board since August 2012 and as Chair of our Board since May 2016. After enjoying the private practice of law as a defense litigator in Michigan and Washington, D.C., she joined Solvay America, Inc. “Solvay” (a chemical and pharmaceutical company) in Houston, Texas. Over the course of a twenty-year career with Solvay, she held the positions of Vice President, Human Resources, President of Solvay Management Services, Global Head of Human Resources and Senior Executive Vice President of Global Ethics and Compliance. During her tenure with Solvay, she served as a director on the board of directors of seven subsidiary companies and as Chair of one subsidiary board. After retiring in 2010 she established a consulting business providing expertise in corporate governance, ethics and compliance, organizational development, executive compensation and strategic human resources. She holds a Bachelor of Sciences degree in Biological Sciences from George Washington University, Washington D.C. and a Juris Doctor degree from Seattle University, Seattle, Washington. She also was a Ph.D. candidate in Pharmacology at both Georgetown University Medical School at Washington, D.C. and Northwestern University Medical School at Chicago, Illinois. She remains an active member of both the Michigan State Bar and the District of Columbia Bar, Washington, D.C.
高管简历
中英对照 | 中文 | 英文- Eckhard Guenther
Eckhard Guenther，2014年10月担任商业发展部副总裁，并担任行政官员。从2008到2014年他是我公司副总裁，负责联盟管理和知识产权；2006年到2008年，他是我们的副总裁和药物研发和临床前开发总监。他于1985年在制药行业开始职业生涯，在我们在德国子公司，位于法兰克福的办公室工作。1990年，他加入我们公司的前身ASTA Medica AG，并在药物化学领域和新药研发领域承担越来越重要的角色。他拥有众多的科学和商业技能，有着多年的创新和联盟建设和管理的成功记录。 Guenther博士于1979年从马丁卢瑟哈雷-威登堡大学获得了化学学位，并于1985年获哈雷-威登堡大学有机合成化学博士学位证书。
Eckhard Guenther was appointed as Managing Director of AEZS Germany in January 2020 and Vice President of Business Development & Alliance Management in 2018. Additionally, over the course of his career he has gained extensive experience across research coordination, project management, intellectual properties and business development. After receiving his Ph.D. in organic chemistry from the Martin-Luther University of Halle-Wittenberg Germany, he started his industrial career at Fahlberg-List Magdeburg in 1985. In 1990 he joined ASTA Medica AG in Frankfurt where he worked in the department of Medicinal Chemistry. During his time at ASTA Medica, Dr. Guenther was significantly involved in the preparation and execution for the spin-off of the biotechnology company Zentaris from ASTA Medica. After the founding of Aeterna Zentaris in 2002 he was appointed to Vice President of Drug Discovery and Preclinical Research. In 2008 he was promoted to Vice President Alliance Management & Intellectual Property and in 2014 he became Vice President of Business Development at Aeterna Zentaris. Dr. Guenther was responsible for the initiation and execution of several R&D and licensing deals with midsize and large international pharmaceutical companies, like Schering Pharma, Solvay, Yakult Honsha, Hikma Pharmaceuticals and Sinopharm A-Think. Dr. Guenther is based in Frankfurt, Germany.- Eckhard Guenther，2014年10月担任商业发展部副总裁，并担任行政官员。从2008到2014年他是我公司副总裁，负责联盟管理和知识产权；2006年到2008年，他是我们的副总裁和药物研发和临床前开发总监。他于1985年在制药行业开始职业生涯，在我们在德国子公司，位于法兰克福的办公室工作。1990年，他加入我们公司的前身ASTA Medica AG，并在药物化学领域和新药研发领域承担越来越重要的角色。他拥有众多的科学和商业技能，有着多年的创新和联盟建设和管理的成功记录。 Guenther博士于1979年从马丁卢瑟哈雷-威登堡大学获得了化学学位，并于1985年获哈雷-威登堡大学有机合成化学博士学位证书。
- Eckhard Guenther was appointed as Managing Director of AEZS Germany in January 2020 and Vice President of Business Development & Alliance Management in 2018. Additionally, over the course of his career he has gained extensive experience across research coordination, project management, intellectual properties and business development. After receiving his Ph.D. in organic chemistry from the Martin-Luther University of Halle-Wittenberg Germany, he started his industrial career at Fahlberg-List Magdeburg in 1985. In 1990 he joined ASTA Medica AG in Frankfurt where he worked in the department of Medicinal Chemistry. During his time at ASTA Medica, Dr. Guenther was significantly involved in the preparation and execution for the spin-off of the biotechnology company Zentaris from ASTA Medica. After the founding of Aeterna Zentaris in 2002 he was appointed to Vice President of Drug Discovery and Preclinical Research. In 2008 he was promoted to Vice President Alliance Management & Intellectual Property and in 2014 he became Vice President of Business Development at Aeterna Zentaris. Dr. Guenther was responsible for the initiation and execution of several R&D and licensing deals with midsize and large international pharmaceutical companies, like Schering Pharma, Solvay, Yakult Honsha, Hikma Pharmaceuticals and Sinopharm A-Think. Dr. Guenther is based in Frankfurt, Germany.
- Nicola Ammer
Nicola Ammer于2018年1月被任命为我们的Vice President，临床开发和首席医疗官。她担任我们的执行官之一。Ammer博士，她任职于AEZS Germany的德国法兰克福办事处，于2002年在CRO业务的制药医学环境中开始了她的职业生涯，并在各种职责递增的职位上获得了临床研发各个方面的经验，包括临床运营总监。她于2015年3月加入AEZS Germany，担任临床项目主管，并于2016年1月接任临床开发主管。她拥有制药医学领域的众多技能，并为Macimorelin成人适应症临床开发计划的成功完成做出了重大贡献。Ammer博士在埃森大学（University of Essen）完成学术研究后，于1995年获得行医执照。她于2004年获得the University of M&252；Nster的医学博士学位文凭，并于2009年获得the University Duisburg-Essen的制药医学理学硕士学位。
Nicola Ammer was appointed as our Vice President, Clinical Development and as Chief Medical Officer in January 2018. She serves as one of our executive officers. Dr. Ammer, who is based in the Frankfurt, Germany office of AEZS Germany, began her career in the pharmaceutical medicine environment in the CRO business in 2002 and gained experience in all aspects of clinical research & development in various positions with increasing responsibility, including a Director of Clinical Operations. She joined AEZS Germany in March 2015 as Clinical Program Director and took over the role of the Head of Clinical Development in January 2016. She possesses numerous skills in the area of pharmaceutical medicine and contributed significantly to the successful completion of the macimorelin clinical development program in the adult indication. Dr. Ammer obtained the license to practice medicine in 1995 after completion of her academic studies at the University of Essen. She was awarded a doctorate diploma in medicine by the University of Münster in 2004 and a Master of Science in Pharmaceutical Medicine by the University Duisburg-Essen in 2009.- Nicola Ammer于2018年1月被任命为我们的Vice President，临床开发和首席医疗官。她担任我们的执行官之一。Ammer博士，她任职于AEZS Germany的德国法兰克福办事处，于2002年在CRO业务的制药医学环境中开始了她的职业生涯，并在各种职责递增的职位上获得了临床研发各个方面的经验，包括临床运营总监。她于2015年3月加入AEZS Germany，担任临床项目主管，并于2016年1月接任临床开发主管。她拥有制药医学领域的众多技能，并为Macimorelin成人适应症临床开发计划的成功完成做出了重大贡献。Ammer博士在埃森大学（University of Essen）完成学术研究后，于1995年获得行医执照。她于2004年获得the University of M&252；Nster的医学博士学位文凭，并于2009年获得the University Duisburg-Essen的制药医学理学硕士学位。
- Nicola Ammer was appointed as our Vice President, Clinical Development and as Chief Medical Officer in January 2018. She serves as one of our executive officers. Dr. Ammer, who is based in the Frankfurt, Germany office of AEZS Germany, began her career in the pharmaceutical medicine environment in the CRO business in 2002 and gained experience in all aspects of clinical research & development in various positions with increasing responsibility, including a Director of Clinical Operations. She joined AEZS Germany in March 2015 as Clinical Program Director and took over the role of the Head of Clinical Development in January 2016. She possesses numerous skills in the area of pharmaceutical medicine and contributed significantly to the successful completion of the macimorelin clinical development program in the adult indication. Dr. Ammer obtained the license to practice medicine in 1995 after completion of her academic studies at the University of Essen. She was awarded a doctorate diploma in medicine by the University of Münster in 2004 and a Master of Science in Pharmaceutical Medicine by the University Duisburg-Essen in 2009.
- Leslie Auld
Leslie Auld于2018年9月被任命为我们的高级副总裁，首席财务官。她拥有超过25年的会计、金融和制药业经验，在普华永道会计师事务所、HELIX BIOPHARMACORP.、Luminex Diagnostics（前身为TM Bioscience Corp.）、Attwell Capital Inc.（前身为Fralex Therapeutics）和GeneNews Limited担任越来越多的高级职务。Auld女士是一名特许专业会计师，以优异成绩毕业于西安大略大学药理学&毒理学理学学士学位，并获得多伦多大学工商管理硕士学位。
Leslie Auld was appointed as our Senior Vice President, Chief Financial Officer in September 2018. She has over twenty-five years of accounting, finance and pharmaceutical industry experience, with increasingly senior roles at PricewaterhouseCoopers, Helix BioPharma Corp., Luminex Diagnostics formerly TM BioScience Corp., Attwell Capital Inc. (formerly Fralex Therapeutics) and GeneNews Limited. A Chartered Professional Accountant, Ms. Auld graduated with an Honors Bachelor of Science degree in Pharmacology & Toxicology from the University of Western Ontario and has a Master of Business Administration degree from the University of Toronto.- Leslie Auld于2018年9月被任命为我们的高级副总裁，首席财务官。她拥有超过25年的会计、金融和制药业经验，在普华永道会计师事务所、HELIX BIOPHARMACORP.、Luminex Diagnostics（前身为TM Bioscience Corp.）、Attwell Capital Inc.（前身为Fralex Therapeutics）和GeneNews Limited担任越来越多的高级职务。Auld女士是一名特许专业会计师，以优异成绩毕业于西安大略大学药理学&毒理学理学学士学位，并获得多伦多大学工商管理硕士学位。
- Leslie Auld was appointed as our Senior Vice President, Chief Financial Officer in September 2018. She has over twenty-five years of accounting, finance and pharmaceutical industry experience, with increasingly senior roles at PricewaterhouseCoopers, Helix BioPharma Corp., Luminex Diagnostics formerly TM BioScience Corp., Attwell Capital Inc. (formerly Fralex Therapeutics) and GeneNews Limited. A Chartered Professional Accountant, Ms. Auld graduated with an Honors Bachelor of Science degree in Pharmacology & Toxicology from the University of Western Ontario and has a Master of Business Administration degree from the University of Toronto.
- Matthias Gerlach
Matthias Gerlach于2014年6月被任命为我们制造业务的Vice President，并于2018年1月被任命为Vice President，制造和供应链。他担任我们的执行官之一。从2011年12月到2014年5月，他曾担任我们的Vice President，负责药物化学。Gerlach博士，他任职于AEZS Germany的法兰克福办事处，于1997年开始了他在制药行业的职业生涯。他于2001年1月加入我们公司，在他的职业生涯中通过产品商业化在药物化学和临床前开发领域承担越来越多的责任。他拥有众多的科学和商业技能，拥有成功的创新、药物开发和管理的长期记录，并为Macimorelin在成人适应症的成功美国商业化做出了重大贡献。Gerlach博士于1994年在法兰克福的Johann Wolfgang Goethe University获得化学文凭，并于1997年被Johann Wolfgang Goethe University授予合成有机化学博士学位。
Matthias Gerlach was appointed as our Vice President, Manufacturing Operations in June 2014 and as Vice President, Manufacturing and Supply Chain in January 2018. He serves as one of our executive officers. From December 2011 through May 2014 he was our Vice President, Medicinal Chemistry. Dr. Gerlach, who is based in the Frankfurt office of AEZS Germany, began his career in the pharmaceutical industry in 1997. He joined our Company in January 2001 assuming roles of increasing responsibility in areas of medicinal chemistry and preclinical development through product commercialization during his career. He possesses numerous scientific and business skills and has a long record of successful innovation, drug development and management and contributed significantly to the successful U.S.-commercialization of macimorelin in the adult indication. Dr. Gerlach obtained a diploma in Chemistry from the Johann Wolfgang Goethe University in Frankfurt in 1994 and was awarded his doctorate diploma in synthetic organic chemistry by the Johann Wolfgang Goethe University in 1997.- Matthias Gerlach于2014年6月被任命为我们制造业务的Vice President，并于2018年1月被任命为Vice President，制造和供应链。他担任我们的执行官之一。从2011年12月到2014年5月，他曾担任我们的Vice President，负责药物化学。Gerlach博士，他任职于AEZS Germany的法兰克福办事处，于1997年开始了他在制药行业的职业生涯。他于2001年1月加入我们公司，在他的职业生涯中通过产品商业化在药物化学和临床前开发领域承担越来越多的责任。他拥有众多的科学和商业技能，拥有成功的创新、药物开发和管理的长期记录，并为Macimorelin在成人适应症的成功美国商业化做出了重大贡献。Gerlach博士于1994年在法兰克福的Johann Wolfgang Goethe University获得化学文凭，并于1997年被Johann Wolfgang Goethe University授予合成有机化学博士学位。
- Matthias Gerlach was appointed as our Vice President, Manufacturing Operations in June 2014 and as Vice President, Manufacturing and Supply Chain in January 2018. He serves as one of our executive officers. From December 2011 through May 2014 he was our Vice President, Medicinal Chemistry. Dr. Gerlach, who is based in the Frankfurt office of AEZS Germany, began his career in the pharmaceutical industry in 1997. He joined our Company in January 2001 assuming roles of increasing responsibility in areas of medicinal chemistry and preclinical development through product commercialization during his career. He possesses numerous scientific and business skills and has a long record of successful innovation, drug development and management and contributed significantly to the successful U.S.-commercialization of macimorelin in the adult indication. Dr. Gerlach obtained a diploma in Chemistry from the Johann Wolfgang Goethe University in Frankfurt in 1994 and was awarded his doctorate diploma in synthetic organic chemistry by the Johann Wolfgang Goethe University in 1997.
- Guenther Grau
Guenther Grau于2018年2月被任命为我们的财务Vice President。Grau先生，自2000年以来一直是公司的一部分。他的制药行业职业生涯始于1995年任职ASTA Medica AG（我们公司的前身公司），在他的职业生涯中担任内部和外部会计领域越来越大的责任。Grau先生于1991年在马尔堡the Philipps-University获得工商管理文凭。
Guenther Grau was appointed as our Vice President, Finance in February 2018. Mr. Grau, has been part of the Company since 2000. He began his career in the pharmaceutical industry at ASTA Medica AG, a predecessor of our Company, in 1995 assuming roles of increasing responsibility in areas of internal and external accounting during his career. Mr. Grau obtained a diploma in Business Administration from the Philipps-University, Marburg, in 1991.- Guenther Grau于2018年2月被任命为我们的财务Vice President。Grau先生，自2000年以来一直是公司的一部分。他的制药行业职业生涯始于1995年任职ASTA Medica AG（我们公司的前身公司），在他的职业生涯中担任内部和外部会计领域越来越大的责任。Grau先生于1991年在马尔堡the Philipps-University获得工商管理文凭。
- Guenther Grau was appointed as our Vice President, Finance in February 2018. Mr. Grau, has been part of the Company since 2000. He began his career in the pharmaceutical industry at ASTA Medica AG, a predecessor of our Company, in 1995 assuming roles of increasing responsibility in areas of internal and external accounting during his career. Mr. Grau obtained a diploma in Business Administration from the Philipps-University, Marburg, in 1991.
- Klaus Paulini
Klaus Paulini于2019年10月被任命为公司总裁兼首席执行官，并担任董事会董事。Paulini博士位于德国法兰克福，隶属于我们的子公司AEZS Germany，他于2019年7月被任命为董事总经理，并于2018年2月被任命为Vice President质量和监管机构。Paulini博士于1997年在ASTA Medica AG开始了他的制药行业职业生涯。他曾在Zentaris公司从ASTA Medica公司成立和剥离时发挥积极作用，并担任公司的多种职务，并不断被提拔，包括Cetrotide公司的项目责任。作为质量保证主管，Paulini博士成功地管理了我们的许多临床开发项目——包括Macrilen™；/Macimorelin——处于研发阶段，担任集团领导药物化学。凭借丰富的经验和知识，他为我们的制药和临床开发计划提供了成功的监督和宝贵的投入，确保成功和合规的结果，最终导致美国FDA和EMA的监管批准。Paulini博士获得博士学位ING博士。1993年在达姆施塔特工业大学（德国）获得化学博士学位，在加入ASTA Medica AG之前，在斯特拉斯克莱德大学（苏格兰格拉斯哥）和J.W.歌德大学（德国法兰克福）获得博士后奖学金期间专门从事药物化学/药物发现。
Klaus Paulini was appointed President and Chief Executive Officer of the Company in October 2019 and also serves as a director on our Board. Dr. Paulini is based in Frankfurt, Germany at our subsidiary AEZS Germany, where he was appointed Managing Director in July 2019 and as Vice President Quality and Regulatory in February 2018. Dr. Paulini began his career in the pharmaceutical industry at ASTA Medica AG in 1997. He had an active role when Zentaris was formed and spun out of ASTA Medica, and served in various roles with increasing responsibility at the company ever since, including project responsibility for Cetrotide®. As Head of Quality Assurance, Dr. Paulini successfully managed many of our clinical development projects - including Macrilen™/Macimorelin - in R&D phase as group leader medicinal chemistry. With his extensive experience and knowledge, he provided successful oversight and valuable input for our pharmaceutical and clinical development programs, ensuring successful and compliant outcomes, ultimately leading to regulatory approvals by the US FDA and the EMA. Dr. Paulini obtained his PhD Dr. Ing. in chemistry at the Technical University Darmstadt (Germany) in 1993 and specialized in medicinal chemistry/drug discovery during subsequent postdoctoral fellowships at Strathclyde University (Glasgow, Scotland) and J.W. Goethe University (Frankfurt, Germany) before joining ASTA Medica AG.- Klaus Paulini于2019年10月被任命为公司总裁兼首席执行官，并担任董事会董事。Paulini博士位于德国法兰克福，隶属于我们的子公司AEZS Germany，他于2019年7月被任命为董事总经理，并于2018年2月被任命为Vice President质量和监管机构。Paulini博士于1997年在ASTA Medica AG开始了他的制药行业职业生涯。他曾在Zentaris公司从ASTA Medica公司成立和剥离时发挥积极作用，并担任公司的多种职务，并不断被提拔，包括Cetrotide公司的项目责任。作为质量保证主管，Paulini博士成功地管理了我们的许多临床开发项目——包括Macrilen™；/Macimorelin——处于研发阶段，担任集团领导药物化学。凭借丰富的经验和知识，他为我们的制药和临床开发计划提供了成功的监督和宝贵的投入，确保成功和合规的结果，最终导致美国FDA和EMA的监管批准。Paulini博士获得博士学位ING博士。1993年在达姆施塔特工业大学（德国）获得化学博士学位，在加入ASTA Medica AG之前，在斯特拉斯克莱德大学（苏格兰格拉斯哥）和J.W.歌德大学（德国法兰克福）获得博士后奖学金期间专门从事药物化学/药物发现。
- Klaus Paulini was appointed President and Chief Executive Officer of the Company in October 2019 and also serves as a director on our Board. Dr. Paulini is based in Frankfurt, Germany at our subsidiary AEZS Germany, where he was appointed Managing Director in July 2019 and as Vice President Quality and Regulatory in February 2018. Dr. Paulini began his career in the pharmaceutical industry at ASTA Medica AG in 1997. He had an active role when Zentaris was formed and spun out of ASTA Medica, and served in various roles with increasing responsibility at the company ever since, including project responsibility for Cetrotide®. As Head of Quality Assurance, Dr. Paulini successfully managed many of our clinical development projects - including Macrilen™/Macimorelin - in R&D phase as group leader medicinal chemistry. With his extensive experience and knowledge, he provided successful oversight and valuable input for our pharmaceutical and clinical development programs, ensuring successful and compliant outcomes, ultimately leading to regulatory approvals by the US FDA and the EMA. Dr. Paulini obtained his PhD Dr. Ing. in chemistry at the Technical University Darmstadt (Germany) in 1993 and specialized in medicinal chemistry/drug discovery during subsequent postdoctoral fellowships at Strathclyde University (Glasgow, Scotland) and J.W. Goethe University (Frankfurt, Germany) before joining ASTA Medica AG.